Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation

Transplant International

Volumn 26, Issue 1, 2013, Pages 67-74

  Sprinzl, Martin F ^a   Weinmann, Arndt ^a   Lohse, Nikola ^a   Tönissen, Hanna ^a   Koch, Sandra ^a   Schattenberg, Jörn ^a   Hoppe Lotichius, Maria ^a   Zimmermann, Tim ^a   Galle, Peter R ^a   Hansen, Torsten ^a   Otto, Gerd ^a   Schuchmann, Marcus ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

body mass index; glycosylated hemoglobin; metabolic syndrome; obesity; risk factors

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGED; FATTY LIVER; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84871309348     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01576.x     Document Type: Article

References (33)

1. Adam R, McMaster P, O'Grady JG, etal. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9: 1231.
2. Desai S, Hong JC, Saab S,. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors, incidence and management. Liver Int 2010; 30: 948.
3. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J,. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901.
4. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR,. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10: 1420.
5. Ekstedt M, Franzen LE, Mathiesen UL, etal. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865.
6. Goessling W, Massaro JM, Vasan RS, D'Agostino Sr RB, Ellison RC, Fox CS,. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135: 1935.
7. Dureja P, Mellinger J, Agni R, etal. NAFLD recurrence in liver transplant recipients. Transplantation 2011; 91: 684.
8. Poordad F, Gish R, Wakil A, Garcia-Kennedy R, Martin P, Yao FY,. De novo non-alcoholic fatty liver disease following orthotopic liver transplantation. Am J Transplant 2003; 3: 1413.
9. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ,. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009; 15: 1662.
10. Shaheen M, Echeverry D, Oblad MG, Montoya MI, Teklehaimanot S, Akhtar AJ,. Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III]. Diabetes Res Clin Pract 2007; 75: 320.
11. Gane EJ,. Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences. Am J Transplant 2011; 12: 531.
12. Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J,. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009; 9: 782.
13. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA,. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249.
14. Marchetti P, Navalesi R,. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000; 23: 482.
15. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL,. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010; 16: 431.
16. Moench C, Barreiros AP, Schuchmann M, etal. Tacrolimus monotherapy without steroids after liver transplantation-a prospective randomized double-blinded placebo-controlled trial. Am J Transplant 2007; 7: 1616.
17. Weiler N, Thrun I, Hoppe-Lotichius M, Zimmermann T, Kraemer I, Otto G,. Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial. Transplantation 2010; 90: 1562.
18. Contos MJ, Cales W, Sterling RK, etal. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486.
20. Ashwell M, Gunn P, Gibson S,. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. Obes Rev 2012; 13: 275.
21. Inzucchi SE, Bergenstal RM, Buse JB, etal. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364.
22. Laryea M, Watt KD, Molinari M, etal. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109.
23. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z,. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011; 17: 15.
24. Ruiz-Rebollo ML, Sanchez-Antolin G, Garcia-Pajares F, etal. Risk of development of the metabolic syndrome after orthotopic liver transplantation. Transplant Proc 2010; 42: 663.
25. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M,. Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14: 1648.
26. Ingram DG, Bachrach BE,. Validation of HbA1c of 6.5% for diagnosing diabetes mellitus via the use of taxometric analysis. Ann Epidemiol 2011; 22: 66.
27. Panzer S, Kronik G, Lechner K, Bettelheim P, Neumann E, Dudczak R,. Glycosylated hemoglobins (GHb): an index of red cell survival. Blood 1982; 59: 1348.
28. Meyer C, Rumpf HJ, Hapke U, Dilling H, John U,. Prevalence of alcohol consumption, abuse and dependence in a country with high per capita consumption: findings from the German TACOS study. Transitions in Alcohol Consumption and Smoking. Soc Psychiatry Psychiatr Epidemiol 2000; 35: 539.
29. Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A,. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009; 15: 1814.
30. Joy D, Thava VR, Scott BB,. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003; 15: 539.
31. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F,. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123.
32. Brandman D, Pingitore A, Lai JC, etal. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl 2011; 17: 1380.
33. Toniutto P, Fabris C, Avellini C, etal. Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation. World J Gastroenterol 2005; 11: 5944.